ClinicalTrials.gov
ClinicalTrials.gov Menu

Serum Maresin-1 Predicts the Severity of Severe Acute Pancreatitis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03364920
Recruitment Status : Not yet recruiting
First Posted : December 7, 2017
Last Update Posted : December 7, 2017
Sponsor:
Information provided by (Responsible Party):
Weiqin Li, Nanjing University School of Medicine

Brief Summary:
This is a retrospective study about serum Maresin-1 level in different severe acute pancreatitis patients. The investigators want to study the correlation between the level of serum Maresin-1 and the severity of SAP, of course the clinical outcomes. The investigators want to find some biomarkers and strategy target drugs of severe acute pancreatitis.

Condition or disease
Pancreatitis, Acute

Study Type : Observational
Estimated Enrollment : 200 participants
Observational Model: Cohort
Time Perspective: Retrospective
Official Title: Serum Maresin-1 Level Predicts the Disease Severity and Clinical Outcomes of Severe Acute Pancreatitis Patients
Estimated Study Start Date : January 1, 2018
Estimated Primary Completion Date : January 1, 2019
Estimated Study Completion Date : January 1, 2020

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Pancreatitis

Group/Cohort
normal level of serum maresin-1
abnormal level of serum maresin-1



Primary Outcome Measures :
  1. mortality [ Time Frame: up to 28 days ]
    The level of serum maresin-1 predicts the severity of severe acute pancreatitis


Secondary Outcome Measures :
  1. The incidence of MODS [ Time Frame: through study completion, an average of 1 year ]
    The level of serum maresin-1 predicts the severity of severe acute pancreatitis

  2. The incidence of IPN [ Time Frame: through study completion, an average of 1 year ]
    The level of serum maresin-1 predicts the severity of severe acute pancreatitis



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population
This study includes severe acute pancreatitis between 18ys and 75ys.Patients with disorder of glucolipide metabolism will be excluded. Alcoholic pancreatitis and HTG-AP patients will be also excluded. Patients will be divided into 2 groups according to their level of serum maresin-1.
Criteria

Inclusion Criteria:

  • Clinical diagnosis of Severe Acute Pancreatitis
  • Biliary pancreatitis
  • 7 days of the onset

Exclusion Criteria:

  • Surgical patients
  • Serious diseases and infection
  • Alcoholic pancreatitis
  • Hypertriglyceridemia pancreatitis
  • Disorder of Glucolipide Metabolism:diabetes mellitus, hypertriglyceridemia, BMI>30

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03364920


Contacts
Contact: Weiqin Li 13962531994 luyingying126@sina.cn

Sponsors and Collaborators
Weiqin Li

Responsible Party: Weiqin Li, Doctor, Nanjing University School of Medicine
ClinicalTrials.gov Identifier: NCT03364920     History of Changes
Other Study ID Numbers: SMPSSAP
First Posted: December 7, 2017    Key Record Dates
Last Update Posted: December 7, 2017
Last Verified: December 2017

Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Keywords provided by Weiqin Li, Nanjing University School of Medicine:
Maresin-1
SAP
IPN
MODS
Mortality

Additional relevant MeSH terms:
Pancreatitis
Pancreatic Diseases
Digestive System Diseases